ESTABLISHED DIAGNOSTIC METHODS
Microscopy and Culture
Microscopic examination of respiratory samples for acid-fast bacilli using the Ziehl-Neelsen and fluorochrome stains, such as the auramine and rhodamine, have been the standard and rapid diagnostic tools for tuberculosis (TB) diagnosis.1,2 Recent advances in light-emitting diode (LED) technology have widened the applicability of fluorescent microscopy.3 In adults and older children, sputum samples are often obtained with sensitivity from 34% to 80%.4 In younger children, who are unable to produce sputum samples, alternative methods of obtaining respiratory samples, such as gastric aspirates, are often used. However, microscopic yields may be <20% in children with probable TB.5 The detection rates on microscopy from other extrapulmonary samples, such as cerebrospinal fluid, are even lower because of the paucibacillary nature of disease at these sites.
Mycobacterial culture of respiratory samples has provided a more useful method of diagnosis in children with suspected pulmonary TB. Three consecutive daily morning gastric aspirates yield M. tuberculosis in 30% to 50% of cases and may be as high as 70% in infants.6 Recently, sputum induction using nebulized hypertonic (3%–5%) saline has been used safely and effectively in young children. The culture yield from a single induced sputum sample has been shown to be equivalent to that of 3 cumulative gastric lavage samples.7 There are, however, some concerns regarding the risk of nosocomial transmission following sputum induction if adequate infection control procedures are not in place. Nasopharyngeal aspiration (NPA) has also been used to obtain respiratory samples, as the passage of a nasal cannula may elicit a cough reflex. The culture yield from NPA (19/64; 30%) was similar to that of gastric aspirates (24/64; 38%) among Peruvian children.8 However, subsequent studies have shown relatively poor yields from NPA samples compared with gastric aspirate.9,10 Since young children tend to swallow their sputum rather than expectorate it, mycobacterial culture of stool has been considered as an indirect way of analysis of respiratory secretions. However, studies in children have shown relatively poor recovery from stool, making this an insensitive method for mycobacterial culture. Furthermore, the major drawback of stool culture is the need for stringent decontamination procedures to prevent overgrowth of normal bowel flora, which may also kill or inhibit growth of mycobacteria further reducing the sensitivity.11
Another novel method of sampling swallowed respiratory secretions is the string test. The string test was developed for the diagnosis of intestinal parasites such as giardiasis. This test involves swallowing a gelatin capsule containing a coiled nylon string, which unravels as the capsule descends into the stomach. After 4 hours, the string is withdrawn and cultured for mycobacteria. Although this test appears to have a better culture yield than sputum induction in adults with HIV infection (9% vs. 5%), it has not been studied in children other than a feasibility study where it appears to have been well tolerated.12,13 Furthermore, it may be of limited use in younger children who will be unable to swallow the capsule in the first place.
The culture yield from other body fluids or tissues from children with extrapulmonary TB is usually <50%.14,15 In children with palpable peripheral lymphadenopathy, fine needle aspiration and culture is a very useful adjunct to culture of respiratory specimens and may have a higher yield than such culture (sensitivity 60.8% vs. 39.2%, respectively).16
Recently, automated liquid culture systems with continuous monitoring for mycobacterial growth (such as BD BACTEC MGIT system or Biomerrieux BacT/ALERT 3D) have been a significant advance over traditional solid culture (Lowenstein-Jensen media). In adult studies, these tests offer improved sensitivity (88% vs. 76%) and reduced detection time (13.2 vs. 25.8 days) compared with solid media.17 It is likely that these findings can be extrapolated to children with TB, although there is a paucity of pediatric data. Despite their higher cost and the laboratory infrastructure required, liquid culture has been recommended for all culture in resource-rich settings.18
Newer culture-based methods, such as TK medium, use multiple dye indicators for the early detection of mycobacterial growth with the naked eye. The simple colorimetric system reduces turnaround times, but their accuracy and robustness in field conditions have not been reported. The Microscopic Observation Drug Susceptibility assay uses an inverted light microscope to rapidly detect mycobacterial growth in liquid growth media. It is an inexpensive method that has demonstrated excellent performance under field conditions (in both adults and children), being more sensitive than standard liquid broth or solid culture media systems.9,19,20 The test is not widely available at present.
Tuberculin Skin Test
A positive tuberculin skin test (TST) reaction has been used as a hallmark of infection with M. tuberculosis, occurring within 3 to 6 weeks, but occasionally up to 3 months, and remaining positive lifelong, even after treatment.21
The Mantoux test is the standard TST currently in use and involves the intradermal injection of 2 standardized tuberculin units of purified protein derivative solution. Subsequent induration, rather than erythema, is measured in millimeters after 48 to 72 hours. In some countries, such as the United Kingdom, with low TB incidence a TST is regarded as positive with induration of >5 mm in those without prior Bacille Calmette-Guérin (BCG) vaccination and >15 mm for those who have received BCG vaccination. The World Health Organization (WHO) guidelines differ slightly in that a positive TST is regarded as positive with induration >10 mm for those without prior BCG vaccination and >15 mm for those with BCG vaccination history.22 The US guidelines use a risk categorization based on epidemiologic and clinical factors: >5 mm (close contacts, TB disease, immunosuppression), >10 mm (increased risk of disseminated disease or increased exposure to TB disease), and >15 mm (children >4 years of age with no risk factors).23
TST is prone to both false-negative and false-positive results. Up to 10% to 15% of otherwise immunocompetent children with culture-documented TB do not initially show TST reactivity.14 Host factors, such as young age, poor nutrition, immunosuppression, other viral infections (such as measles, varicella, and influenza), recent TB infection, and disseminated TB diseases, can further decrease TST reactivity. False-positive TST results may also occur following BCG vaccination and exposure to environmental nontuberculous mycobacteria.24 Skin reactivity can be boosted, probably through antigenic stimulation, by serial testing with TST in many children and adults who received BCG.25
Chest radiography is used widely for the detection of pulmonary TB, including detection of hilar lymphadenopathy, lung parenchymal changes, and miliary TB. Cavitary disease is uncommon in younger children but is often seen in adolescents, who may develop adult-type postprimary disease.26 Computed tomography imaging has been useful in demonstrating early pulmonary disease, such as cavitation, and intrathoracic hilar lymphadenopathy.27 Central nervous system disease, such as TB meningitis or tuberculoma, may also be identified on computed tomography imaging, where meningeal enhancement may be seen with contrast. Magnetic resonance imaging has been found to be useful for musculoskeletal TB, particularly involving bones and joints.28
ADVANCES IN DIAGNOSIS
Novel Culture Systems and Detection Methods
Bacteriophage-based assays use bacteriophage viruses to infect and detect the presence of viable M. tuberculosis in clinical samples and culture isolates. Two main approaches have been developed: (1) to detect the presence of mycobacteria using either phage amplification and (2) to detect light produced by luciferase reporter phages after their infection of live M. tuberculosis. When the assays detect M. tuberculosis in drug-free samples, but fail to detect M. tuberculosis in drug-containing samples, the strains are classified as drug susceptible. In general, phage assays have a turn around time of 2 to 3 days and require a laboratory infrastructure similar to that required for standard cultures. There is currently only 1 commercially available kit, the FASTPlaque-TB (Biotec Laboratories, Ipswich, Suffolk, United Kingdom) assay, which can be used directly on sputum samples for diagnosis. A variant of this assay, the FASTPlaque-Response kit is designed to detect rifampicin resistance in sputum specimens, which has been used as a reliable marker for multidrug-resistant TB. However, no information exists on the utility of these tests in the diagnosis of childhood TB.
The potential of a gas sensor array electronic “nose” (E-nose) to detect different Mycobacterium species in the headspaces of cultures and sputum samples is another innovative approach that is currently under development. The array uses 14 sensors to profile a “smell” by assessing the change in each sensor's electrical properties when exposed to a specific odor mixture. In a recent study using sputum samples from adult TB patients and non-TB patients, the E-nose had sensitivity of 68% and specificity of 69%.29 Further research is still required to improve sensitivity and specificity as well as its potential in the diagnosis of childhood TB.
Molecular Diagnostics and Rapid Resistance Testing
Nucleic acid amplification tests (NAATs) for the detection of mycobacterial DNA or RNA are increasingly being developed for clinical use. These tests are theoretically highly sensitive, able to detect very low copy numbers of nucleic acid, rapid, not requiring biosafety level 3 facilities and are relatively easy to automate. Commercial NAATs have been extensively evaluated in adults showing high specificity (85%–98%), high sensitivity for smear-positive TB (pooled estimate 96%) but poorer sensitivity for smear-negative TB (pooled estimate 66%).11 Sensitivity estimates are generally also lower in most paucibacillary forms of disease, including extrapulmonary, which represents most of childhood TB cases. Their performance in children has not been thoroughly evaluated; however, limited studies to date suggest that their performance in children is likely to be similar to that in smear-negative adults because of the paucibacillary nature of TB in children.3
There have been several recent evaluations of NAATs performed on nonrespiratory samples to diagnosis respiratory disease. One study has reported the presence of small fragments of M. tuberculosis IS6110 DNA in urine (so-called transrenal DNA or tr-DNA) of 34 of 43 adults with TB but not in healthy controls.30 However, other studies have shown wide variations in performance (7%–100% sensitivity), and there are no data on the performance of these tests in children. A urinary test that could serve as a rapid and easy diagnostic test has advantages in the pediatric population.
NAATs have also been used for the rapid detection of rifampicin resistance directly from sputum samples. The Xpert MTB/RIF is a cartridge-based, automated diagnostic test that is rapid and simple to use and correctly identified 98% of bacteria that were resistant to rifampicin in a large study in adults.31 In December 2010, WHO endorsed this test for use in TB endemic countries and declared it a major milestone for global TB diagnosis.
As mentioned earlier in the text, young children swallow their sputum, and thus DNA of M. tuberculosis may be detected in stool. At present, there are limited data in children, although in several small studies, the sensitivity appears low (<40%) compared with adults (sensitivity 86%).32,33
Real-time polymerase chain reaction has increasingly become available for clinical use with the advantage of lower cross-contamination and as well as the ability to identify rifampicin resistance. The rpoB gene of M. tuberculosis accounts for >95% of rifampicin resistance, and because rifampicin resistance is usually accompanied by isoniazid resistance (monoresistance is rare), this test is used as a marker for multidrug-resistant TB.
Line probe assays (LPAs) are NAATs that simultaneously detect infection with M. tuberculosis and amplify regions of drug resistance. LPAs use strip technology, whereby amplified DNA is applied to strips containing probes specific for M. tuberculosis, isoniazid, and rifampicin resistance. The WHO has endorsed LPAs for culture and smear-positive clinical specimens as part of a larger commitment to target and implement new technology in high-burden countries.34
Because of the limitations of TST, particularly cross-reactivity with BCG immunization and environmental mycobacteria, newer diagnostic tests have been the developed based on in vitro T-cell-based interferon-γ release assays (IGRA), which measure interferon-γ production in response to stimulation to TB-specific antigens (ESAT-6, CFP10 and in QuantiFERON TB Gold TB 7.7). These antigens are present in M. tuberculosis complex but absent from all strains of Mycobacterium bovis BCG, and almost all environmental mycobacteria. Two IGRAs—the QuantiFERON-TB Gold assay (Cellestis Limited, Carnegie, Victoria, Australia) and the T SPOT-TB assay (Oxford Immunotec, Oxford, United Kingdom)—are currently available. Both tests measure interferon-γ release from T cells using enzyme-linked immunosorbent assay and enzyme-linked immunospot assay, respectively.35
IGRAs have been studied in both LTBI and active disease in different geographic settings. As there is no gold standard for LTBI, exposure gradients have been used and comparison made with TST. Overall, although evidence is limited, the results show that IGRAs have modest predictive value, perhaps of the same magnitude as TST. For the diagnosis of LTBI, there is a high agreement between the IGRAs but much discordance (mostly TST-positive/IGRA-negative) between the IGRA test and TST. The high specificity of IGRAs may be useful in reducing the number of low-risk children who receive preventative therapy.36
In low TB incidence settings, there was higher specificity of IGRA (100% and 98% for Quantiferon-TB (QFT). and T-Spot, respectively) than TST (58%) in children with TB disease However, in children with nontuberculous mycobacteria (NTM) and other respiratory infections, TST had 100% sensitivity compared with 93% for IGRA.37 Two studies in children with TB disease from the United Kingdom have shown lower sensitivity of IGRA compared with TST >15 mm (83%, 80%, and 58% for TST, QFT, and T-spot and 82%, 78%, and 66% for TST, QFT, and T-spot, respectively).38,39 In both studies, the sensitivities increased to >90% when the combined IGRA and TST result was used to diagnose definite TB. Overall for active disease, IGRAs have suboptimal sensitivity and therefore cannot be used in isolation to rule out TB disease in children. Although IGRAs may be used to help support a diagnosis of TB, in combination with the TST and other investigations, they should not be a substitute, or obviate the need, for appropriate specimen collection. Furthermore, IGRA cannot distinguish between LTBI and active disease, similar to the TST. Further work is needed to determine the added value of IGRAs, beyond conventional tests such as microbiology and chest radiographs for the diagnosis of active TB disease.
The other significant problem encountered with IGRA testing has been the risk of indeterminate tests, particularly in younger children and the immunocompromised individuals.40 Rates of indeterminates appear to be generally higher in Quantiferon TB GOLD than enzyme-linked immunospot assay in young children and immunosupressed individuals.41,42
Another immune-based approach has been the measurement of the immune response to transdermal application of M. tuberculosis MPB-64 antigen. In pilot studies, the MPB-64 skin patch test successfully distinguished active TB from LTBI (88%–98% sensitivity, 100% specificity).43
Novel Detection Methods
A recent innovative approach that has been explored is the urinary detection of lipoarabinomannan (LAM). LAM is a 17.5-kD glycolipid component of the outer cell wall of mycobacteria. LAM is heat stable, cleared by the kidney, and detectable in urine. As a bacterial product, it has the theoretical potential to discriminate active TB from latent infection, the former having higher quantities of bacteria. The sensitivity of urinary LAM in adults varies widely (44%–67%).44,45 Higher estimates have been reported in HIV-coinfected patients with advanced immunosuppression, presumably because of higher bacterial burden and increased frequency of disseminated disease.46 At present, there are limited data for urinary LAM in children.
Advances in the diagnosis of childhood TB in the past decade have included the identification of alternative specimen types as well as improvement in smear microscopy and liquid culture systems. A number of novel and exciting methods have been identified for diagnosis of adult TB, such as integrated real-time polymerase chain reaction detection systems, urine LAM, and testing for volatile organic compounds in breath. However, many of these novel diagnostics have not been studied in children, and further research in this area is greatly needed.
1. Ba F, Rieder H. A comparison of fluorescence microscopy with the Ziehl-Neelsen technique in the examination of sputum for acid-fast bacilli. Int J Tuberc Lung Dis. 1999;3:1101–1105.
2. Steingart K, Henry M, Ng V, et al.. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6:570–581.
3. Marais B, Brittle W, Painczyk K, et al.. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis. 2008;47:203–207.
4. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children 1999. Am J Respir Crit Care Med. 2000;161:1376–1395.
5. Strumpf I, Tsang A, Syre J. Re-evaluation of sputum staining for the diagnosis of pulmonary tuberculosis. Am Rev Respir Dis. 1979;119:599–602.
6. Vallejo J, Ong L, Starke J. Clinical features, diagnosis and treatment of tuberculosis in infants. Pediatrics. 1994;94:1–7.
7. Zar H, Hanslo D, Apolles P, et al.. Induced sputum versus gastric lavage for microbiological confirmation if pulmonary tuberculosis in infants and young children: a prospective study. Lancet. 2005;365:130–134.
8. Franchi L, Cama R, Gilman R, et al.. Detection of Mycobacterium tuberculosis
in nasopharyngeal aspirate samples in children. Lancet. 1998;352:1681–1682.
9. Oberhelman R, Soto-Castellares G, Caviedes L, et al.. Improved recovery of Mycobacterium tuberculosis
from children using the microscopic observation drug susceptibility method. Pediatrics. 2006;118:e100–e106.
10. Al-Aghbari N, Al-Sonboli N, Yassin M, et al.. Multiple sampling in one day to optimize smear microscopy in children with tuberculosis in Yemen. PLoS One. 2009;4:e5140.
11. Nicol M, Zar H. New Specimens and laboratory diagnostics for childhood pulmonary TB: progress and prospects. Paediatr Respir Rev. 2011;12:16–21.
12. Vargas D, Garcia L, Gilman R, et al.. Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru. Lancet. 2005;365:150–152.
13. Chow F, Espiritu N, Gilman R, et al.. La cuerda dulce-a tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis. BMC Infect Dis. 2006;6:67.
14. Starke J, Taylor-Watts K. Tuberculosis in the pediatric population of Houston, Texas. Pediatrics. 1989;84:28–35.
15. Teo S, Riordan A, Alfaham M, et al.. Tuberculosis in the United Kingdom and Republic of Ireland. Arch Dis Child. 2009;94:263–267.
16. Wright C, Hesseling AC, Bamford C, et al.. Fine needle aspiration biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral tuberculosis suspects with peripheral lymphadenopathy. Int J Tuberc Lung Dis. 2009;13:1373–1379.
17. Cruciani M, Scarparo C, Malena M, et al.. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004;42:2321–2325.
18. National Institute of Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control: Royal College of Physicians of London; 2006.
19. Moore D, Evans C, Gilman R, et al.. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006;355:1539–1550.
20. Arias M, Mello F, Pavon A, et al.. Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. Clin Infect Dis. 2007;44:674–680.
21. Hsu K. Tuberculin reaction in children treated with isoniazid. Am J Dis Child. 1983;137:1090–1092.
22. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 5th ed. Geneva: World Health Organization; 1997.
23. American Academy of Pediatrics. Tuberculosis. In: PL K., editor. Red Book: 2009 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.
24. Larsson L, Bentzon M, Lind A, et al.. Sensitivity to sensitins and tuberculin in Swedish Children. Part 5: a study of school children in an inland rural area. Tubercle Lung Dis. 1993;74:371–376.
25. Sepulveda R, Burr C, Ferrer X, et al.. Booster effect of tuberculin testing in healthy 6-yearpold school children vaccinated with bacille Calmette-Guerin at birth in Santiago, Chile. Pediatr Infect Dis J. 1988;7:578–582.
26. Khan E, Starke J. Diagnosis of tuberculosis in children: increased need for better methods. Emerg Infect Dis. 1995;1:115–123.
27. Andronikou S, Joseph E, Lucas S, et al.. CT scanning for the detection of tuberculous mediastinal and hilar lymphadenopathy in children. Pediatr Radiol. 2004;34:232–236.
28. De Backer A, Mortele K, Vanhoenacker F, et al.. Imaging of extraspinal musculoskeletal tuberculosis. Eur J Radiol. 2006;57:119–130.
29. Kolk A, Hoelscher M, Maboko L, et al.. Electronic-nose technology using sputum samples in diagnosis of patients with tuberculosis. J Clin Microbiol. 2010;48:4235–4238.
30. Cannas A, Goletti D, Girardi E, et al.. Mycobacterium tuberculosis
DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2008;12:146–151.
31. Boehme C, Nabeta P, Hilleman D, et al.. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–1015.
32. Wolf H, Mendez M, Gilman R, et al.. Diagnosis of pediatric tuberculosis by stool PCR. Am J Trop Med Hyg. 2008;79:893–898.
33. Cordova J, Shiloh R, Gilman R, et al.. Evaluation of molecular tools for detection and drug susceptibility testing of Mycobacterium tuberculosis
in stool specimens from patients with pulmonary tuberculosis. J Clin Microbiol. 2010;48:1820–1826.
34. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization; 2008.
35. Lalvani A, Nagvenkar P, Udwadia Z, et al.. Enumeration of T cells specific for RDi-encoded antigens suggest a high prevalence of latent mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis. 2001;183:469–477.
36. Ling D, Zwerling A, Steingart K, et al.. Immune-based diagnostics for TB in children: what is the evidence? Paediatr Respir Rev. 2011;12:9–15.
37. Detjen A, Keil T, Roll S, et al.. Interferon-gamma release assays improve the diagnosis of tuberculosis and non-tuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis. 2007;45:322–328.
38. Kampmann B, Whittaker E, Williams A, et al.. Interferon-gamma release assays do not identify more children with active tuberculosis that the tuberculin skin test. Eur Respir J. 2009;33:1374–1382.
39. Bamford A, Crook A, Clark J, et al.. Comparison of interferon-gamma release assays and tuberculin skin test in predicting active tuberculosis in children in the UK: a paediatric TB network study. Arch Dis Child. 2010;95:180–186.
40. Haustein T, Ridout D, Hartley J, et al.. The likelihood of an indeterminate test result from a whole-blood interferon gamma release assay for the diagnosis of mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis. 2009;28:669–673.
41. Bergamini B, Losi M, Vaienti F, et al.. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics. 2009;123:e419–e424.
42. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a meta-analysis. Chest. 2010;137:952–968.
43. Nakamura R, Einck L, Velmonte M, et al.. Detection of active tuberculosis by an MPB-64 transdermal patch: a field study. Scand J Infect Dis. 2001;33:405–407.
44. Boehme C, Molokova E, Minja F, et al.. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg. 2005;99:893–900.
45. Mutetwa R, Boehme C, Dimairo M, et al.. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009;13:1253–1259.
46. Lawn S, Edwards D, Kranzer K, et al.. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy, diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23:1875–1880.
tuberculosis; diagnosis; child